Compare NICE Ltd (NICE) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Spyre Therapeutics Inc. Common Stock — how do they compare? NICE Ltd trades at $110.41 (market cap $6.90B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: NICE Ltd and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NICE Ltd for 16 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NICE | SYRE | |
|---|---|---|
Market Cap | $6.90B | $7.52B |
Volume | 665,954 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $136.90 | $108.92 |
52-Week Low | $83.15 | $22.18 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $6.63B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NICE stock trades at $114.95, down 0.08% on the day, with a bullish technical signal from moving averages and key support at $113. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.70 exceeding the $2.63 estimate. Revenue reached $2.95 billion in 2025, though net income is projected to decline to $425 million in 2026. Analyst consensus is a Buy with a $124.20 price target, and recent news highlights leadership in AI-driven contact center platforms.
The outlook for NICE is positive, driven by AI revenue growth and a low valuation, but investors face risks from margin compression due to heavy AI investments and competitive pressures. The stock's current price offers a potential 8% upside to the consensus target, supported by institutional buying interest and solid cash flow generation.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
